Atogepant vs placebo for the preventative treatment of migraine alleviated migraine symptoms across 3 clinical trials on day 1.

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

The American College of Physicians issues new guidance on the prevention of episodic migraine with pharmacologic treatment recommendations.

The American College of Physicians (ACP) has developed new recommendations for treatment of acute episodic migraines in nonpregnant adults in outpatient settings.

CEFALY Technology, maker of the #1 neuromodulation treatment for migraine, announced today it has selected PayrHealth, the industry's leading Complete Payor Management solution, to manage payor ...

While over-the-counter medications often provide relief, natural remedies such as menthol are gaining popularity for their ...

Topiramate, which is also an anti-seizure medicine, is currently the only US Food and Drug Administration (FDA) medication ...

Lasmiditan is a promising treatment for menstrual migraine, offering sustained pain relief comparable to or exceeding that of triptans. However, further research is needed to fully assess its safety ...

Migraine is much more than just a headache. It is a debilitating disease that can drastically impact the lives of those affected, limiting their ability to work, study, travel, spend time with ...

Migraine disrupts daily life with invisible neurological pain, causing physical, emotional, and cognitive struggles that go ...

DARIEN, Conn., March 6, 2025 /PRNewswire/ -- CEFALY Technology, maker of the #1 neuromodulation treatment for migraine, announced today it has selected PayrHealth, the industry's leading Complete ...